Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 1998-09-11 (27 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: FEURS (42110), Loire
PHARMACIE MERMIER BON : revenue, balance sheet and financial ratios
PHARMACIE MERMIER BON is a French company
founded 27 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in FEURS (42110),
this company of category PME
shows in 2023 a revenue of 1.6 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE MERMIER BON (SIREN 420121535)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
1 630 122 €
N/C
N/C
1 433 418 €
933 569 €
1 289 481 €
1 291 094 €
1 329 122 €
Net income
132 007 €
75 740 €
144 849 €
124 892 €
105 366 €
100 891 €
3 455 €
45 843 €
992 €
6 864 €
EBITDA
N/C
N/C
168 798 €
N/C
N/C
121 441 €
-23 281 €
11 290 €
-34 179 €
-19 718 €
Net margin
N/C
N/C
8.9%
N/C
N/C
7.0%
0.4%
3.6%
0.1%
0.5%
Revenue and income statement
In 2025, PHARMACIE MERMIER BON generates positive net income of 132 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 7 k€ -> 132 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
132 007 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 54%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 58%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
53.547%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
58.049%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
4.006
3.363
2.386
160.567
131.777
115.793
84.585
76.635
63.011
53.547
Financial autonomy
80.72
80.791
83.482
33.797
38.482
42.407
47.505
50.201
53.746
58.049
Repayment capacity
5.113
681.438
0.54
226.012
6.34
None
None
3.871
None
None
Cash flow / Revenue
0.573%
0.004%
3.489%
0.364%
8.398%
None%
None%
9.525%
None%
None%
Sector positioning
Debt ratio
53.552025
2023
2024
2025
Q1: 13.57
Med: 49.47
Q3: 128.28
Average
In 2025, the debt ratio of PHARMACIE MERMIER BON (53.55) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
58.05%2025
2023
2024
2025
Q1: 33.69%
Med: 53.88%
Q3: 72.26%
Good
In 2025, the financial autonomy of PHARMACIE MERMIER BON (58.0%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
3.87 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Average
In 2023, the repayment capacity of PHARMACIE MERMIER BON (3.87) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 258.50. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
147.187
142.216
168.612
161.49
196.596
330.829
208.725
258.103
212.88
258.504
Interest coverage
0.0
0.0
0.0
-1.276
2.395
None
None
2.305
None
None
Sector positioning
Liquidity ratio
258.52025
2023
2024
2025
Q1: 131.48
Med: 182.6
Q3: 258.72
Good
In 2025, the liquidity ratio of PHARMACIE MERMIER BON (258.50) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
2.31x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of PHARMACIE MERMIER BON (2.3x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE MERMIER BON
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
84 931 €
81 029 €
104 835 €
127 666 €
185 040 €
0 €
0 €
166 321 €
0 €
0 €
Inventory turnover (days)
34
36
36
46
37
0
0
38
0
0
Customer payment term (days)
8
4
6
8
6
0
0
6
0
0
Supplier payment term (days)
40
47
46
57
42
0
0
36
0
0
Positioning of PHARMACIE MERMIER BON in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE MERMIER BON is estimated at
2 096 946 €
(range 1 422 998€ - 3 290 398€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1422k€2096k€3290k€
2 096 946 €Range: 1 422 998€ - 3 290 398€
NAF 5 année 2025
Valuation method used
Net Income Multiple
132 007 €
×
15.9x
=2 096 947 €
Range: 1 422 998€ - 3 290 398€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE MERMIER BON with other companies in the same sector:
Frequently asked questions about PHARMACIE MERMIER BON
What is the revenue of PHARMACIE MERMIER BON ?
The revenue of PHARMACIE MERMIER BON in 2023 is 1.6 M€.
Is PHARMACIE MERMIER BON profitable?
Yes, PHARMACIE MERMIER BON generated a net profit of 132 k€ in 2025.
Where is the headquarters of PHARMACIE MERMIER BON ?
The headquarters of PHARMACIE MERMIER BON is located in FEURS (42110), in the department Loire.
Where to find the tax return of PHARMACIE MERMIER BON ?
The tax return of PHARMACIE MERMIER BON is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE MERMIER BON operate?
PHARMACIE MERMIER BON operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart